About

I have spent more than 25 years in drug development and medical communications, working as a medical writer, publications lead, and medical affairs director across US and European functions at companies including Amgen, Sanofi, Dendreon, and DaVita.

Throughout that career I managed budgets, contracted with freelancers and medical communications agencies, and worked directly with legal and accounts payable teams on both sides of the table — as a client engaging vendors, and as a consultant building project scope and pricing from the ground up. Understanding how both sides operate shapes every engagement.

What I bring to every engagement is the ability to work across clinical, real-world, and outcomes evidence — integrating PK, safety, efficacy, PRO, and HEOR data into coherent scientific narratives. I understand how the pieces fit together across functions and audiences.

Grounded in scientific integrity and a commitment to helping teams move from data to impact.

Core Capabilities

Publication planning and execution Lifecycle-aligned and RWE-aligned publication strategies, authorship engagement, congress planning, and manuscript development in accordance with GPP and ICMJE guidelines.
Medical content writing and editing Peer-reviewed manuscripts, congress materials, slide decks, value dossiers, and field-facing resources tailored to target audiences.
Medical affairs strategic support Advisory board planning and execution, insight synthesis, and cross-functional collaboration across medical, clinical, HEOR, and commercial functions.

Therapeutic Areas

Oncology Immunotherapy Nephrology Rheumatology Dermatology HEOR Real-world evidence

Contact

Email helen@wilfehrtconsulting.com
Phone +1 (805) 630-9803
Address Henderson mailbox — pending

Portfolio

Co-authored Journal Articles

Antonarakis ES, Subudhi SK, Pieczonka CM, Karsh LI, Quinn DI, Hafron JM, Wilfehrt HM, Harmon M, Sheikh NA, Shore ND, Petrylak DP. Combination treatment with sipuleucel-T and abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer: STAMP and STRIDE trials. Clin Cancer Res 2023;29(13):2426–34. doi:10.1158/1078-0432.CCR-22-3832.

Hafron JM, Wilfehrt HM, Ferro C, Harmon M, Flanders SC, McKay RR. Real-world effectiveness of sipuleucel-T on overall survival in men with advanced prostate cancer treated with androgen receptor-targeting agents. Adv Ther. 2022;37:4910–492. doi:10.1007/s12325-022-02085-6.

McKay RR, Hafron JM, Ferro C, Wilfehrt HM, Fitch K, Flanders SC, Fabrizio MD, Schweizer MT. A retrospective observational analysis of overall survival with sipuleucel-T in Medicare beneficiaries treated for advanced prostate cancer. Adv Ther. 2020;37(12):4910–4929. doi:10.1007/s12325-020-01509-5.

Krishnan M, Wilfehrt HM, Lacson Jr E. In data we trust: The role and utility of dialysis provider databases in the policy process. Clin J Am Soc Nephrol. 2012;7(11):1891–6. doi:10.2215/CJN.03220312.

Hazard E, Cherry SB, Lalla D, Woolley JM, Wilfehrt H, Chiou CF. Clinical and economic burden of psoriasis. Manag Care Interface. 2006;19(4):20–6. PMID: 16689023.

Wilfehrt HM, Carson CC 3rd, Marson L. Bladder function in female rats: effects of aging and pregnancy. Physiol Behav 1999;(1-2):195–203. doi:10.1016/s0031-9384(99)00175-4.

Morrison SF, Cravo SL, Wilfehrt HM. Pontine lesions produce apneusis in the rat. Brain Res. 1994;25;652(1):83–86. doi:10.1016/0006-8993(94)90320-4.

Co-authored Conference Publications

Bond TC, Mutell R, Wilfehrt HM, and Krishnan M. Association of pruritis and quality of life (QOL) among patients at a large dialysis provider. 33rd Annual Dialysis Conference (ADC). Seattle, WA. 2013.

Sibbel S, Bond TC, Wilfehrt HM, Nissenson A, Krishnan M. Decreased population hemoglobin (HB) levels and increased transfusion (TFN) rates under new ESA guidelines in patients (PTS) with ESRD at a large dialysis organization (LDO). Am J Kidney Dis. 2013;61. Presented at International Conference on Glomerular Diseases.

Bond TC, Marlowe G, Wilfehrt HM, Young A, Krishnan M, Mayne TJ. Patient-reported pruritus rates and indicators of infection co-vary directly among patients receiving dialysis. American Society of Nephrology Kidney Week. San Diego, CA, Oct 30–Nov 4, 2012. Abstract TH-PO267.

Sura AC, Marson L, Wilfehrt HM, et al. Role of endogenous 5 HT1A receptors in male sexual behavior. Society for Neuroscience Annual Meeting. 1999. Miami, Florida.

Wilfehrt HM, Marson L. Aging and pregnancy effects on in vivo and in vitro bladder function in female rats. Society for Neuroscience Annual Meeting. 1998. Los Angeles, California.

Wilfehrt HM, Marson L. Role of brainstem sites in the regulation of micturition in female rats. Society for Neuroscience Annual Meeting. 1997. New Orleans, Louisiana.

Wilfehrt HM, Morrison SF. Diminished responses of spontaneously hypertensive rats to lesions of the caudal ventrolateral medulla. Society for Neuroscience Annual Meeting. 1994. Miami, Florida.

Wilfehrt HM, Morrison SF. Diminished caudal ventrolateral medulla function in spontaneously hypertensive rats. 48th Annual Fall Conference and Scientific Sessions of the American Heart Association Council for High Blood Pressure Research. 1994. Chicago, Illinois.

Wilfehrt HM, McCrimmon DR, Morrison SF. The effect of lesions in the caudal ventrolateral medulla on the frequency components of sympathetic nerve activities. Society for Neuroscience Annual Meeting. 1993. Washington, D.C.